Assuit University, South Egypt Cancer InstituteSECI Oncology Journal2537-09958220200516The role of PANE1 as a model for minor histocompatibility restricted antigen in hematopoietic stem cell transplantation for leukemic patients12179742010.21608/secioj.2020.97420ENJournal Article20200407Background: In hematopoietic stem cell transplantation (HSCT), minor histocompatibility antigens (MiHA) can be used as tools for immunotherapy especially if they are restricted to hematopoietic cells like PANE1 MiHA. <br /> <br />Purpose of study: We aimed at studying PANE1 as MiHA model in human leucocyte antigen (HLA) matched related Egyptian HSCT patients regarding its frequency and the effect of mismatching in PANE1 on HSCT outcomes. <br /> <br />Methods: Ninety-six patient/donor pairs were studied for the prevalence of disparities in PANE1 MiHA and its effect on graft versus host disease (GvHD) and graft versus leukemia (GvL). A sequence- specific primer (SSP) approach was used to determine the immunogenic (PANER) and non-immunogenic (PANES) alleles of PANE1 gene. Student ttest, Mann-Whitney U test, ANOVA F-test, and Kruskal-Wallis H tests were used to determine the significance of the difference for quantitative data. Relations of qualitative data were determined using Chi-square test. Survival analysis was done using Kaplan-Meier method to determine overall survival (OS). <br /> <br />Results: High prevalence PANER allele of PANE1 was observed in both patients and donors (192/192,100% of 96 patient/donor pairs). Mismatches in PANE1 gene were observed in 9 patient /donor pairs. Nine cases showed relapse post-transplantation and there was no association between PANE1 mismatch and relapse (p=0.8). <br /> <br />Conclusion: No association between mismatches in PANE1 gene and any transplant - related outcome was observed. Which might decrease its use as a target for immunotherapy in Egyptian leukemia patients.Assuit University, South Egypt Cancer InstituteSECI Oncology Journal2537-09958220200609Long-term outcomes after robotic minimally invasive esophagectomy for esophageal squamous cell carcinoma18249742110.21608/secioj.2020.97421ENJournal Article20200506Background: The use of the minimally invasive surgery robotic esophagectomy (RE) for esophageal cancer (EC) has been increasing over the past decade, as it reduces morbidity and mortality compared with other surgical approaches. However, although the technical feasibility and safety of RE for EC have been reported, few studies have evaluated oncological outcomes. This retrospective cohort study aimed to determine the long-term outcomes of RE for EC. Methods: Twenty-four consecutive patients who underwent RE with total mediastinal lymph node dissection for EC between 2009 and 2013 were enrolled in this study. The short- and long- term outcomes, including the 5-year overall survival (5yOS) and 5-year recurrence-free survival (5yRFS) rates, were examined retrospectively. Results: With a median follow-up of 37 months, the 5yOS was 70.8% and the 5yRFS was 62.5%. Tumor recurrence was found in nine (37.5%) patients, and liver metastasis, the most common site of recurrence, was seen in five (20.8%) patients. Multivariate analysis demonstrated that pathological tumor stage (pT ≥ 2) and certain late complications of surgery as measured by the Clavien–Dindo (CD) classification (pneumonia CD grade II and stenosis CD grade III) were significantly associated with 5yOS, while pT ≥ 2 and pN ≥ 1 were significantly associated with 5yRFS. Anastomotic leakage was the most common complication, observed in seven (29.2%) patients. The median number of harvested lymph nodes was 41 and 13 patients (54.2%) had node-positive disease. Conclusions: We have shown that RE for EC is not only safe and feasible but also has encouraging oncological outcomes. We also demonstrated that late complications are significantly associated with long-term survival. Confirmation in a prospective study would assure the place of RE in the management of EC with curative intent.